Krystal Biotech, Inc.
General ticker "KRYS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.6B (TTM average)
Krystal Biotech, Inc. follows the US Stock Market performance with the rate: 53.0%.
Estimated limits based on current volatility of 2.0%: low 321.58$, high 334.65$
Factors to consider:
- Total employees count: 295 (+7.3%) as of 2025
- Top business risk factors: Dependence on VYJUVEK, Regulatory and compliance, Clinical trial failure, Manufacturing scale up, Intellectual property risks
- Current price 18.1% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [176.05$, 268.05$]
- 2026-12-31 to 2027-12-31 estimated range: [174.98$, 268.47$]
Financial Metrics affecting the KRYS estimates:
- Negative: with PPE of 36.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 41.45 > 33.79
- Positive: 2.37 < Operating cash flow per share per price, % of 2.77
- Positive: Inventory ratio change, % of 1.06 <= 1.34
- Positive: Interest expense per share per price, % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -0.81 <= -0.14
- Positive: Shareholder equity ratio, % of 91.44 > 81.92
Short-term KRYS quotes
Long-term KRYS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $50.70MM | $290.51MM | $389.13MM |
| Operating Expenses | $160.43MM | $224.82MM | $227.84MM |
| Operating Income | $-109.73MM | $65.69MM | $161.29MM |
| Non-Operating Income | $122.62MM | $29.66MM | $28.18MM |
| R&D Expense | $46.43MM | $53.58MM | $58.05MM |
| Income(Loss) | $12.90MM | $95.36MM | $189.47MM |
| Taxes | $1.97MM | $6.20MM | $-15.36MM |
| Net Income(Loss)* | $10.93MM | $89.16MM | $204.83MM |
| Stockholders Equity | $778.64MM | $946.38MM | $1,219.56MM |
| Inventory | $6.99MM | $26.51MM | $40.48MM |
| Assets | $818.36MM | $1,055.84MM | $1,333.79MM |
| Operating Cash Flow | $-88.80MM | $123.42MM | $200.87MM |
| Capital expenditure | $11.80MM | $4.24MM | $11.95MM |
| Investing Cash Flow | $82.64MM | $-163.44MM | $-58.42MM |
| Financing Cash Flow | $202.75MM | $27.01MM | $8.71MM |
| Earnings Per Share** | $0.40 | $3.12 | $7.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.